10q10k10q10k.net
ACCURAY INC

ACCURAY INCARAYEarnings & Financial Report

Nasdaq

Accuray is a radiation therapy company that develops, manufactures, and sells radiation therapy systems to deliver treatments including stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). It is the developer of innovative technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, the latest generation TomoTherapy platform. The company is headquartered in Sunnyvale, CA, the United States. The platforms are installed in leading healthcare ...

NextMay 2, 2026

ARAY Q2 2026 Key Financial Metrics

Revenue

$102.2M

Gross Profit

$24.1M

Operating Profit

$-11.6M

Net Profit

$-13.8M

Gross Margin

23.5%

Operating Margin

-11.3%

Net Margin

-13.5%

YoY Growth

-12.0%

EPS

$-0.11

Financial Flow

ACCURAY INC Q2 2026 Financial Summary

ACCURAY INC reported revenue of $102.2M for Q2 2026, with a net profit of $-13.8M (-13.5% margin). Cost of goods sold was $78.2M, operating expenses totaled $35.6M.

Key Financial Metrics

Total Revenue$102.2M
Net Profit$-13.8M
Gross Margin23.5%
Operating Margin-11.3%
Report PeriodQ2 2026

ACCURAY INC Annual Revenue by Year

ACCURAY INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $458.5M).

YearAnnual Revenue
2025$458.5M
2024$446.6M
2023$447.6M
2022$429.9M

Income Statement

Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Revenue$101.1M$134.3M$101.5M$116.2M$113.2M$127.5M$93.9M$102.2M
YoY Growth-14.3%13.5%-2.3%8.3%12.0%-5.0%-7.5%-12.0%

Balance Sheet

Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Assets$462.5M$468.6M$473.1M$478.4M$484.3M$470.2M$456.8M$448.0M
Liabilities$421.4M$423.5M$427.9M$430.5M$434.7M$389.1M$394.9M$394.6M
Equity$41.1M$45.1M$45.2M$47.9M$49.6M$81.2M$61.9M$53.4M

Cash Flow

Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Operating CF$-8.1M$9.9M$-7.3M$1.8M$18.1M$-9.7M$12.2M$-16.0M